News
We curate articles on recent biotech advancements that exemplify our investment thesis. These highlight human-centric innovations with potential for high returns and cost efficiencies. Sources are linked for further reading. Breakthrough in Biological Quantum Sensors
December 15, 2025
Researchers at MIT developed a quantum sensor detecting enzymatic activity in live human cells, reducing diagnostic costs by 60% compared to traditional methods. This aligns with PCBI’s focus on non-invasive, animal-free tech.
Source: Science Journal Article
Advancements in Next-Generation Omics
November 28, 2025
A startup using multi-omics AI platforms identified new cancer biomarkers from human datasets alone, slashing drug development timelines from years to months and avoiding animal trials.
Source: BioTech News
Conformational Energy Landscapes Unlock New Drugs
October 30, 2025
Using computational simulations, scientists mapped protein landscapes to design PROTACs for neurodegeneration, cutting costs by 70% through in silico predictions. No animal data required.
Source: Nature Biotechnology
In-Cell Time-Resolved Methods Revolutionize Screening
September 25, 2025
New FRET-based techniques captured dynamic protein interactions in human cells, enabling faster, cheaper drug modality testing with 95% predictive accuracy over animal models.
Source: Cell Press
Solubility Enhancement Excipients Industry Overview and Leading Players
February 2, 2025
The Solubility Enhancement Excipients market is a critical component of the pharmaceutical industry, playing a vital role in the development of formulations that enhance the solubility of active pharmaceutical ingredients (APIs). With the increasing complexity of drug formulations and a growing demand for more effective delivery systems, excipients that enhance solubility have become indispensable.
Source: OpenPR
In pharma’s competitive climate, companies need evidence beyond clinical trials
January, 21, 2025
Early planning and market research are crucial in an era of rising cost pressures.
Source: Pharma Voice
Why 90% of clinical drug development fails and how to improve it?
February 11, 2022
Ninety percent of clinical drug development fails despite implementation of many successful strategies, which raised the question whether certain aspects in target validation and drug optimization are overlooked?
Source: NIH
Excipient Innovation Through Precompetitive Research
December 20, 2021
